

1 **Pituitary stem cells produce paracrine WNT signals to control the**
2 **expansion of their descendant progenitor cells**

3 John Parkin Russell¹, Xinhong Lim^{2,3}, Alice Santambrogio^{1,4}, Val Yianni¹, Yasmine
4 Kemkem⁵, Bruce Wang^{6,7}, Matthew Fish⁶, Scott Haston⁸, Anaëlle Grabek⁹, Shirleen
5 Hallang¹, Emily Jane Lodge¹, Amanda Louise Patist¹, Andreas Schedl⁹, Patrice
6 Mollard⁵, Roeland Nusse⁶, Cynthia Lilian Andoniadou^{1,4,*}

7

8 ¹ Centre for Craniofacial and Regenerative Biology, King's College London, Floor 27 Tower
9 Wing, Guy's Campus, London, SE1 9RT, United Kingdom

10 ² Skin Research Institute of Singapore, Agency for Science, Technology and Research,
11 Singapore 308232

12 ³ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
13 308232

14 ⁴ Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität
15 Dresden, 01307 Dresden, Germany

16 ⁵ Institute of Functional Genomics (IGF), University of Montpellier, CNRS, INSERM, F-
17 34094 Montpellier, France

18 ⁶ Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA
19 94305-5329; Department of Developmental Biology, Stanford University School of
20 Medicine, Stanford, CA 94305-5329, USA

21 ⁷ Department of Medicine and Liver Center, University of California San Francisco, San
22 Francisco, CA 94143-1346, USA

23 ⁸ Developmental Biology and Cancer, Birth Defects Research Centre, UCL GOS Institute of
24 Child Health, London, WC1N 1EH, United Kingdom

25 ⁹ Université Côte d'Azur, Inserm, CNRS, iBV, Nice 06108, France.

26

27 * Corresponding author

28 E-mail: cynthia.andoniadou@kcl.ac.uk. Phone: +44 20 7188 7389. Fax: +44 20 7188 1674

29

30

31

32 **ABSTRACT**

33

34 In response to physiological demand, the pituitary gland generates new hormone-
35 secreting cells from committed progenitor cells throughout life. It remains unclear to
36 what extent pituitary stem cells (PSCs), which uniquely express SOX2, contribute to
37 pituitary growth and renewal. Moreover, neither the signals that drive proliferation
38 nor their sources have been elucidated. We have used genetic approaches in the
39 mouse, showing that the WNT pathway is essential for proliferation of all lineages in
40 the gland. We reveal that SOX2⁺ stem cells are a key source of WNT ligands. By
41 blocking secretion of WNTs from SOX2⁺ PSCs *in vivo*, we demonstrate that
42 proliferation of neighbouring committed progenitor cells declines, demonstrating that
43 progenitor multiplication depends on the paracrine WNT secretion from SOX2⁺
44 PSCs. Our results indicate that stem cells can hold additional roles in tissue expansion
45 and homeostasis, acting as paracrine signalling centres to coordinate the proliferation
46 of neighbouring cells.

47

48

49

50 **KEY WORDS**

51 SOX2, paracrine signal, WNT, pituitary gland, stem cell, feedforward regulation

52 INTRODUCTION

53 How stem cells interact with their surrounding tissue has been a topic of
54 investigation since the concept of the stem cell niche was first proposed (Schofield,
55 1978). Secreted from supporting cells, factors such as WNTs, FGFs, SHH, EGF and
56 cytokines, regulate the activity of stem cells (Nabhan et al., 2018; Palma et al., 2005;
57 Tan and Barker, 2014). Furthermore, communication is known to take place in a bi-
58 directional manner (Doupe et al., 2018; Tata and Rajagopal, 2016).

59 The anterior pituitary (AP) is a major primary endocrine organ that controls
60 key physiological functions including growth, metabolism, reproduction and the stress
61 responses and exhibits tremendous capability to remodel its constituent hormone
62 populations throughout life, in response to physiological demand. It contains a
63 population of *Sox2* expressing stem cells that self-renew and give rise to lineage-
64 committed progenitors and functional endocrine cells (Andoniadou et al., 2013;
65 Rizzoti et al., 2013). During embryonic development, SOX2⁺ undifferentiated
66 precursor cells of Rathke's pouch, the pituitary anlage (Arnold et al., 2011; Castinetti
67 et al., 2011; Fauquier et al., 2008; Pevny and Rao, 2003), generate all committed
68 endocrine progenitor lineages, defined by the absence of SOX2 and expression of
69 either POU1F1 (PIT1), TBX19 (TPIT) or NR5A1 (SF1) (Bilodeau et al., 2009; Davis
70 et al., 2011). These committed progenitors are proliferative and give rise to the
71 hormone-secreting cells. Demand for hormone secretion rises after birth, resulting in
72 dramatic organ growth and expansion of all populations by the second postnatal week
73 (Carbajo-Perez and Watanabe, 1990; Taniguchi et al., 2002). SOX2⁺ pituitary stem
74 cells (PSCs) are most active during this period, but the bulk of proliferation and organ
75 expansion during postnatal stages derives from SOX2⁻ committed progenitors. The
76 activity of SOX2⁺ PSCs gradually decreases and during adulthood is minimally

77 activated even following physiological challenge (Andoniadou et al., 2013; Gaston-
78 Massuet et al., 2011; Gremeaux et al., 2012; Zhu et al., 2015). By adulthood,
79 progenitors carry out most of the homeostatic functions, yet SOX2⁺ PSCs persist
80 throughout life in both mice and humans (Gonzalez-Meljem et al., 2017; Xekouki et
81 al., 2018). The signals driving proliferation of committed progenitor cells are not
82 known, and neither is it known if SOX2⁺ PSCs can influence this process beyond
83 their minor contribution of new cells.

84 The self-renewal and proliferation of numerous stem cell populations relies
85 upon WNT signals (Basham et al., 2019; Lim et al., 2013; Takase and Nusse, 2016;
86 Wang et al., 2015; Yan et al., 2017). WNTs are necessary for the initial expansion of
87 Rathke's pouch as well as for PIT1 lineage specification (Osmundsen et al., 2017;
88 Potok et al., 2008). In the postnatal pituitary, the expression of WNT pathway
89 components is upregulated during periods of expansion and remodelling. Gene
90 expression comparisons between neonatal and adult pituitaries or in GH-cell ablation
91 experiments (Gremeaux et al., 2012; Willems et al., 2016), show that the WNT
92 pathway is upregulated during growth and regeneration.

93 Our previous work revealed that during disease, the paradigm of supporting
94 cells signalling to the stem cells may be reversed; mutant stem cells expressing a
95 degradation-resistant β -catenin in the pituitary, promote cell non-autonomous
96 development of tumours through their paracrine actions (Andoniadou et al., 2013;
97 Gonzalez-Meljem et al., 2017). Similarly, degradation-resistant β -catenin expression
98 in hair follicle stem cells led to cell non-autonomous WNT activation in neighbouring
99 cells promoting new growth (Deschene et al., 2014). In the context of normal
100 homeostasis, stem cells have been shown to influence daughter cell fate in the
101 mammalian airway epithelium and the *Drosophila* gut via 'forward regulation'

102 models, where the fate of a daughter cell is directed by a stem cell via juxtacrine
103 Notch signalling (Ohlstein and Spradling, 2007; Pardo-Saganta et al., 2015). It
104 remains unknown if paracrine stem cell action can also promote local proliferation in
105 normal tissues.

106 Here, we used genetic approaches to determine if paracrine stem cell action
107 takes place in the anterior pituitary and to discern the function of WNTs in pituitary
108 growth. Our results demonstrate that postnatal pituitary expansion, largely driven by
109 committed progenitor cells, depends on WNT activation. Importantly, we show that
110 SOX2⁺ PSCs are the key regulators of this process, acting through secretion of WNT
111 ligands acting in a paracrine manner on neighbouring progenitors. Identification of
112 this forward-regulatory model elucidates a previously unidentified function for stem
113 cells during tissue expansion.

114

115

116 **RESULTS**

117 **WNT-responsive cells in the pituitary include progenitors driving major** 118 **postnatal expansion.**

119 To clarify which cells respond to WNT signals in the postnatal anterior pituitary, we
120 first characterised the anterior pituitary cell types activating the WNT pathway at P14,
121 a peak time for organ expansion and a time point when a subpopulation of SOX2⁺
122 stem cells are proliferative. The *Axin2-CreERT2* mouse line (van Amerongen et al.,
123 2012) has been shown to efficiently label cells with activated WNT signalling in the
124 liver, lung, breast, skin, testes and endometrium among other tissues (Lim et al., 2013;
125 Moiseenko et al., 2017; Syed et al., 2020; van Amerongen et al., 2012; Wang et al.,
126 2015). *Axin2* positive cells were labelled by GFP following tamoxifen induction in

127 *Axin2*^{CreERT2/+}; *R26*^{mTmG/+} mice and pituitaries were analysed 2 days post-induction.

128 We carried out double immunofluorescence staining using antibodies against
129 uncommitted (SOX2), lineage committed (PIT1, TPIT, SF1), and hormone-
130 expressing endocrine cells (GH, PRL, TSH, ACTH or FSH/LH) together with
131 antibodies against GFP labelling the WNT-activated cells. We detected WNT-
132 responsive cells among all the different cell types of the anterior pituitary including
133 SOX2⁺ PSCs, the three committed populations and all hormone-secreting cells
134 (Figure 1A, SFigure 1A).

135 To confirm if the three committed lineages as well as uncommitted SOX2⁺
136 PSCs all expand in response to WNT, we further lineage-traced *Axin2*-expressing
137 cells for 14 days after tamoxifen administration at P14. Double labelling revealed an
138 increase in all four populations between 2 and 14 days (Figure 1A, B). This increase
139 reached significance for the PIT1 (13.7% at 2 days to 30.3% at 14 days, $P=0.000004$)
140 and TPIT (3.78% to 11.03%, $P=0.008$) populations, but not SF1 (0.5% to 4%, n.s.).
141 Only a minority of SOX2⁺ PSCs were WNT-responsive at 2 days (0.57%) and this
142 population expanded to 2% at 14 days (n.s.), suggesting that these are self-renewing.
143 GFP⁺ cells were traced for a period of 8 weeks post-induction, which revealed that
144 WNT-responsive descendants continued to expand at the same rate as the rest of the
145 pituitary (n=4-8 mice per time point at P16, P21, P28, P42, P70) (Figure 1C, D). The
146 time period between 2 and 7 days saw the greatest increase in GFP⁺ cells, during
147 which, the labelled population nearly tripled in size (Figure 1D). The persistence of
148 labelled cells was evident in longer-term traces using the *R26*^{lacZ/+} reporter
149 (*Axin2*^{CreERT2/+}; *R26*^{lacZ/+}), up to a year following induction at P14 (Figure 1E, n=4).
150 Clonal analysis using the Confetti reporter, demonstrated that individual *Axin2*-
151 expressing cells (*Axin2*^{CreERT2/+}; *R26*^{Confetti/+}) gave a greater contribution after four

152 weeks compared to lineage-tracing from *Sox2*-expressing cells
153 (*Sox2^{CreERT2/+};R26^{Confetti/+}*), in support of predominant expansion from WNT-
154 responsive lineage-committed progenitors (SFigure 1B).

155 During times of greater physiological demand, the pituitary engages a
156 proliferative response mirroring that observed during physiological growth (Levy,
157 2002; Nolan et al., 1998). To investigate if this is accompanied by an enhanced WNT
158 response, we induced short-term physiological challenge through the induction of
159 hypothyroidism in wild type juvenile mice for one week from P21. Feeding on an
160 iodine-deficient diet supplemented with 0.15% propylthiouracil (PTU) for one week
161 led to an increase in the number of new TSH-expressing thyrotrophs compared to
162 control animals feeding on normal diet (SFigure 1C), as well as an increase in
163 dividing cells marked by pH-H3 (SFigure 1D). This was accompanied by an elevation
164 in *Axin2* mRNA transcripts (SFigure 1E) confirming an activation of the WNT
165 response.

166 To establish if signalling mediated by β -catenin is necessary for organ
167 expansion we carried out deletion of *Ctnnb1* in the *Axin2⁺* population from P14
168 during normal growth (*Axin2^{CreERT2/+};Ctnnb1^{lox(ex2-6)/lox(ex2-6)}* hereby
169 *Axin2^{CreERT2/+};Ctnnb1^{LOF/LOF}*). Due to morbidity, likely due to *Axin2* expression in
170 other organs, we were limited to analysis up to 5 days post-induction. This resulted in
171 a significant reduction in the number of dividing cells lacking β -catenin, marked by
172 pH-H3 (40% reduction, SFigure 1F, $P=0.0313$), confirming that activation of the
173 WNT pathway is necessary for expansion of the pituitary populations. Taken together,
174 these results confirm that postnatal AP expansion depends on WNT-responsive
175 progenitors across all lineages, in addition to SOX2⁺ PSCs (Figure 1F).

176

177 **WNT/ β -catenin signalling is required for long-term anterior pituitary expansion**
178 **from SOX2⁺ pituitary stem cells.**

179 We further explored the role of WNT pathway activation in postnatal SOX2⁺ stem
180 cells. To permanently mark WNT-responsive cells and their descendants whilst
181 simultaneously marking SOX2⁺ PSCs, we combined the tamoxifen-inducible
182 *Axin2*^{CreERT2/+}; *R26*^{tdTomato/+} with the *Sox2-Egfp* strain, where cells expressing SOX2
183 are labelled by EGFP (*Axin2*^{CreERT2/+}; *Sox2*^{Egfp/+}; *R26*^{tdTomato/+}). Following tamoxifen
184 administration from P21, tdTomato- and EGFP-labelled cells were analysed by flow
185 sorting after 72h, by which point all induced cells robustly express tdTomato (Figure
186 2A). Double-labelled cells comprised 1.5-2% of the SOX2⁺ population (Figure 2A,
187 arrowheads), with the majority of tdTomato⁺ cells found outside of the SOX2⁺
188 compartment. It was previously shown that only around 2.5-5% of SOX2⁺ PSCs have
189 clonogenic potential through *in vitro* assays (Andoniadou et al., 2012; Andoniadou et
190 al., 2013; Perez Millan et al., 2016). To determine if WNT-responsive SOX2⁺ cells
191 are stem cells capable of forming colonies, we isolated double positive
192 tdTomato⁺;EGFP⁺ cells (i.e. *Axin2*⁺; *Sox2*⁺) as well as the single-expressing
193 populations and plated these in equal numbers in stem cell-promoting media at clonal
194 densities (Figure 2B). Double positive tdTomato⁺;EGFP⁺ cells showed a significant
195 increase in the efficiency of colony formation compared to single-labelled EGFP⁺
196 cells (average 9% compared to 5%, *n*=5 pituitaries, *P*=0.0226, Mann-Whitney *U* test
197 (two-tailed)), demonstrating WNT-responsive SOX2⁺ PSCs have a greater clonogenic
198 potential under these *in vitro* conditions, confirming *in vivo* data in Figure 1B. As
199 expected from previous work, none of the single-labelled tdTomato⁺ cells (i.e. SOX2
200 negative) were able to form colonies (Andoniadou et al., 2012).

201 To confirm that PSCs with active WNT signalling through β -catenin have a
202 greater propensity to form colonies *in vitro*, we analysed postnatal pituitaries from
203 *TCF/Lef:H2B-EGFP* mice, reporting the activation of response to WNT signals. This
204 response is detected through expression of an EGFP-tagged variant of histone H2B,
205 which is incorporated into chromatin (Ferrer-Vaquer et al., 2010). At P21, EGFP⁺
206 cells were abundant in all three lobes and particularly in the marginal zone harbouring
207 SOX2⁺ stem cells (SFigure 2A). Through double mRNA *in situ* hybridisation against
208 *Egfp* and *Sox2* in *TCF/Lef:H2B-EGFP* pituitaries, we confirmed that *Sox2*-expressing
209 cells activate H2B-EGFP expression at this time point (SFigure 2B). Isolation by
210 fluorescence-activated cell sorting and *in vitro* culture of the postnatal EGFP⁺
211 compartment revealed an enrichment of cells with clonogenic potential in the
212 EGFP^{High} fraction compared to EGFP^{Low} or negative cells (SFigure 2C, $n=5$
213 pituitaries). Together these results reveal that a proportion of postnatal SOX2⁺ stem
214 cells respond to WNTs through downstream β -catenin/TCF/LEF signalling and that
215 these cells have greater clonogenic capacity *in vitro*.

216 To further address the role of the canonical WNT response in the activity of
217 SOX2⁺ PSCs *in vivo*, we expressed a loss-of-function allele of β -catenin specifically
218 in *Sox2*-expressing cells (*Sox2*^{CreERT2/+}; *Ctnnb1*^{lox(ex2-6)/lox(ex2-6)} hereby
219 *Sox2*^{CreERT2/+}; *Ctnnb1*^{LOF/LOF}) from P14. Twenty-two weeks following induction at
220 P168, there was a substantial drop in the number of cycling cells in the pituitary of
221 *Sox2*^{CreERT2/+}; *Ctnnb1*^{LOF/LOF} mutants compared to *Sox2*^{+/+}; *Ctnnb1*^{LOF/LOF} controls
222 (Figure 2C, $n=2$ pituitaries per genotype). This was accompanied by anterior pituitary
223 hypoplasia following the loss of *Ctnnb1* in SOX2⁺ PSCs (Figure 2D). Therefore, the
224 proliferative capacity of *Ctnnb1*-deficient SOX2⁺ PSCs and of their descendants was
225 impaired long-term, leading to reduced growth. *In vivo* genetic tracing of targeted

226 cells over the 22-week period (*Sox2*^{CreERT2/+}; *Ctnnb1*^{LOF/+}; *R26*^{mTmG/+} compared to
227 *Sox2*^{CreERT2/+}; *Ctnnb1*^{LOF/LOF}; *R26*^{mTmG/+} pituitaries) revealed that targeted (*Ctnnb1*-
228 deficient) SOX2⁺ PSCs were capable of giving rise to the three committed lineages
229 PIT1, TPIT and SF1 (SFigure 2D), indicating that the loss of *Ctnnb1* does not prevent
230 differentiation of SOX2⁺ PSCs into the three lineages. Downregulation of β -catenin
231 was confirmed by immunofluorescence in SOX2⁺ (mGFP⁺) derivatives (SFigure 2E).
232 In conclusion, WNT/ β -catenin signalling is cell-autonomously required to promote
233 the expansion of all pituitary populations (Figure 2E).

234

235 **SOX2⁺ stem cells express WNT ligands.**

236 Having established that WNT activation is responsible for promoting proliferation in
237 the AP, we next focused on identifying the source of WNT ligands. *Axin2* expressing
238 cells from *Axin2*^{CreERT2/+}; *R26*^{mTmG/+} mice were labelled at P14 by tamoxifen induction.
239 Cells expressing *Axin2* at the time of induction are labelled by GFP expression in the
240 membrane. Double immunofluorescence staining for GFP together with SOX2
241 revealed that *Axin2* expressing cells (mGFP⁺) are frequently located in close
242 proximity to SOX2⁺ PSCs (Figure 3A). Two-dimensional quantification of the two
243 cell types revealed that over 50% of mGFP⁺ cells were in direct contact with SOX2⁺
244 nuclei ($n=3$ pituitaries, >500 SOX2⁺ cells per gland, Figure 3A). The analysis did not
245 take into account the cellular processes of SOX2⁺ cells. These results led us to
246 speculate that SOX2⁺ PSCs may be a source of key WNT ligands promoting
247 proliferation of lineage-committed cells.

248 In order to determine if SOX2⁺ PSCs express WNT ligands, we carried out
249 gene expression profiling of SOX2⁺ and SOX2⁻ populations at P14, through bulk
250 RNA-sequencing. Pure populations of *Sox2*-expressing cells excluding lineage-

251 committed populations, were isolated from *Sox2^{Egfp/+}* male and female pituitaries at
252 P14 based on EGFP expression as previously shown (Andoniadou et al., 2012)
253 (Figure 3B, SFigure 3A). Analysis of global gene expression signatures using ‘Gene
254 Set Enrichment Analysis’ (GSEA) (Subramanian et al., 2005) identified a significant
255 enrichment of molecular signatures related to EMT, adherens and tight junctions in
256 the EGFP⁺ fraction, characteristic of the SOX2⁺ population (SFigure 3B). The SOX2⁺
257 fraction also displayed enrichment for genes associated with several signalling
258 pathways known to be active in these cells, including EGFR (Iwai-Liao et al., 2000),
259 Hippo (Lodge et al., 2016; Lodge et al., 2019; Xekouki et al., 2019), MAPK (Haston
260 et al., 2017), FGF (Higuchi et al., 2017), Ephrin (Yoshida et al., 2015; Yoshida et al.,
261 2017) and p53 (Gonzalez-Meljem et al., 2017) (SFigure 3C, Supplementary Table 1).
262 Additionally, PI3K, TGFβ and BMP pathway genes were significantly enriched in the
263 SOX2⁺ population (SFigure 3C, Supplementary Table 1). Query of the WNT-
264 associated genes did not suggest a global enrichment in WNT targets (e.g. enrichment
265 of *Myc* and *Jun*, but not of *Axin2* or *Lef1*) (SFigure 3D, Supplementary Table 1).
266 Instead, SOX2⁺ PSCs expressed a unique transcriptomic fingerprint of key pathway
267 genes including *Lgr4*, *Znrf3*, *Rnf43* capable of regulating WNT signal intensity in
268 SOX2⁺ PSCs, as well as enriched expression of the receptors *Fzd1*, *Fzd3*, *Fzd4*, *Fzd6*
269 and *Fzd7* (SFigure 3D). The predominant R-spondin gene expressed in the pituitary
270 was *Rspo4*, specifically by the EGFP-negative fraction (SFigure 3D). The gene
271 profiling revealed that *Wls* expression, encoding Gpr177/WLS, a necessary mediator
272 of WNT ligand secretion (Carpenter et al., 2010; Takeo et al., 2013; Wang et al.,
273 2015), is enriched in SOX2⁺ PSCs (Figure 3C). Analysis of *Wnt* gene expression
274 confirmed enriched expression of *Wnt2*, *Wnt5a* and *Wnt9a* in SOX2⁺ PSCs, and the
275 expression of multiple additional *Wnt* genes by both fractions at lower levels (SOX2⁺

276 fraction: *Wnt5b*, *Wnt6*, *Wnt16*; SOX2⁻ fraction: *Wnt2*, *Wnt2b*, *Wnt3*, *Wnt4*, *Wnt5a*,
277 *Wnt5b*, *Wnt9a*, *Wnt10a*, *Wnt16*) (Figure 3D). These results reveal that SOX2⁺ PSCs
278 express the essential components to regulate activation of the WNT pathway and
279 express *Wnt* genes as well as the necessary molecular machinery to secrete WNT
280 ligands.

281

282 **Paracrine signalling from SOX2⁺ stem cells promotes WNT activation.**

283 We sought to conclusively determine if WNT secretion specifically from SOX2⁺
284 PSCs drives proliferation of surrounding cells in the postnatal pituitary gland. We
285 proceeded to delete *Wls* only in the *Sox2*-expressing population (*Sox2*^{CreERT2/+}; *Wls*^{fl/fl})
286 from P14 by a series of tamoxifen injections. Due to morbidity, we limited analyses to
287 one week following induction. Pituitaries appeared mildly hypoplastic at P21 along
288 the medio-lateral axis (SFigure 4). To determine if this is a result of reduced
289 proliferation, we carried out immunofluorescence using antibodies against Ki-67 and
290 SOX2. This revealed significantly fewer cycling cells in the SOX2⁻ population of
291 *Sox2*^{CreERT2/+}; *Wls*^{fl/fl} mutant pituitaries compared to *Sox2*^{+/+}; *Wls*^{fl/fl} controls (10.326%
292 Ki-67 in control compared to 3.129% in mutant, $P=0.0008$, unpaired *t*-test) (Figure
293 4A). Additionally, we observed a reduction of cycling cells within the SOX2⁺
294 population (5.582% Ki-67 in control compared to 2.225% in induced
295 *Sox2*^{CreERT2/+}; *Wls*^{fl/fl} mutant pituitaries, $P=0.0121$, unpaired *t*-test) (Figure 4A). To
296 determine if reduced levels of WNT activation accompanied this phenotype, we
297 carried out double mRNA *in situ* hybridisation using specific probes against *Lef1* and
298 *Sox2*. There was an overall reduction in *Lef1* expression in mutants compared to
299 controls, in which we frequently observed robust expression of *Lef1* transcripts in
300 close proximity to cells expressing *Sox2* (arrows, Figure 4B). Together, our data

301 support a paracrine role for SOX2⁺ pituitary stem cells in driving the expansion of
302 committed progeny through the secretion of WNT ligands (Figure 4C).

303

304 **DISCUSSION**

305 Emerging disparities between the archetypal stem cell model, exhibited by the
306 haematopoietic system, and somatic stem cells of many organs, have led to the
307 concept that stem cell function can be executed by multiple cells not fitting a typical
308 stem cell paradigm (Clevers and Watt, 2018). In organs with persistent populations
309 possessing typical functional stem cell properties yet contributing minimally to
310 turnover and repair, the necessity for such classical stem cells is questioned. Here we
311 show that WNT signalling is required for postnatal pituitary growth by both SOX2⁺
312 PSCs as well as SOX2⁻ committed progenitors. We identify an additional discreet
313 function for SOX2⁺ PSCs, where these signal in a feedforward manner by secreting
314 WNT ligands as cues to stimulate proliferation and promote tissue growth.

315 Consistent with previous reports, our data support that SOX2⁺ PSCs
316 contribute, but do not carry out the majority of tissue expansion during the postnatal
317 period (Zhu et al., 2015); instead, new cells primarily derive from more committed
318 progenitors, which we show to be WNT-responsive. We demonstrate that this
319 population of lineage-restricted WNT-responsive cells rapidly expands and
320 contributes long-lasting clones from postnatal stages. It remains to be shown if cells
321 among the SOX2⁻ lineage-committed populations may also fall under the classical
322 definition of a stem cell. Preventing secretion of WNT ligands from SOX2⁺ PSCs
323 reveals that far from being dispensable, paracrine actions of the SOX2⁺ population
324 that are inactive in their majority, are necessary for anterior lobe expansion from
325 lineage-committed populations. In the adrenal, R-spondins are necessary for cortical

326 expansion and zonation, where deletion of *Rspo3*, expressed by the capsule which
327 contains adrenocortical stem cells, results in reduced proliferation of the underlying
328 steroidogenic cells (Vidal et al., 2016). Corroborating a model where committed
329 pituitary progenitors depend on the paracrine actions of SOX2⁺ PSCs, Zhu and
330 colleagues observed that in pituitaries with reduced numbers of PSCs, proliferation
331 among PIT1⁺ cells was significantly impaired (Zhu et al., 2015). It would be
332 intriguing to see if there is a reduction in WNT signalling in this model, or following
333 genetic ablation of adult SOX2⁺ PSCs (Roose et al., 2017).

334 We show that a sub-population of SOX2⁺ PSCs in the postnatal gland are also
335 WNT-responsive and have greater *in vitro* colony-forming potential under defined
336 conditions. This colony-forming potential is normally a property of a minority of
337 SOX2⁺ PSCs at any given age and reflects their *in vivo* proliferative capacity
338 (Andoniadou et al., 2012; Rizzoti et al., 2013). A role for the WNT pathway in
339 promoting SOX2⁺ cell activity is supported by studies showing that pathogenic
340 overexpression of β -catenin promotes their colony-forming ability (Sarkar et al.,
341 2016), and their *in vivo* expansion (Andoniadou et al., 2012). Additionally, elevated
342 WNT pathway activation has been described for pituitary side-population cells,
343 enriched for SOX2⁺ stem cells from young, compared to old pituitaries (Gremeaux et
344 al., 2012). This is in line with our findings that the WNT pathway has an important
345 function in promoting the activation of SOX2⁺ PSCs. It remains to be shown if this
346 response relies on autocrine WNT-signalling as for other stem cells (Lim et al., 2013),
347 however our results reveal reduced proliferation among SOX2⁺ PSCs when WNT
348 secretion from these cells is abolished, supportive of either autocrine signalling, or
349 paracrine signalling between different subsets of the SOX2⁺ population.

350 The mechanism preventing the majority of SOX2⁺ PSCs from responding to
351 WNT signals remains elusive but points to heterogeneity among the population. Such
352 regulation could occur at the level of receptor signalling; we have shown by bulk
353 transcriptomic profiling that SOX2⁺ PSCs express the receptors required to respond to
354 the WNT pathway, but also express high levels of the frizzled inhibitor *Znrf3*, and the
355 R-spondin receptor *Lgr4*. One conceivable scenario is that high levels of *Znrf3* inhibit
356 frizzled receptors in the absence of R-spondin under normal physiological conditions,
357 suppressing a WNT response. In support of this, R-spondins have been shown to
358 promote pituitary organoid formation (Cox et al., 2019). Whether the R-
359 spondin/LGR/ZNRF3 module is active under physiological conditions needs to be
360 determined. Furthermore, well-described factors expressed in PSCs are known to
361 have inhibitory effects on β -catenin-mediated transcription, such as YAP/TAZ
362 (Azzolin et al., 2014; Gregorieff et al., 2015) and SOX2 itself (Alatzoglou et al.,
363 2011; Kelberman et al., 2008).

364 In summary, we demonstrate an alternative mechanism for stem cell
365 contribution to homeostasis, whereby these can act as paracrine signalling hubs to
366 promote local proliferation. Applicable to other organs, this missing link between
367 SOX2⁺ PSCs and committed cell populations of the anterior pituitary, is key for basic
368 physiological functions and renders stem cells integral to organ expansion.

369 MATERIALS AND METHODS

370 Mice

371 All procedures were performed under compliance of the Animals (Scientific
372 Procedures) Act 1986, Home Office License and KCL Ethical Review approval. KCL
373 Biological Services Unit staff undertook daily animal husbandry. Genotyping was
374 performed on ear biopsies taken between P11 and P15 by standard PCR using the
375 indicated primers. These experiments were not conducted at random and the
376 experimenters were not blind while conducting the animal handling and assessment of
377 tissue. Images are representative of the respective genotypes.

378 For lineage tracing studies male *Axin2^{CreERT2/+}* or *Sox2^{CreERT2/+}* mice were bred with
379 homozygous *ROSA26^{mTmG/mTmG}* or *ROSA26^{Confetti/Confetti}* dams to produce the
380 appropriate allele combinations on the reporter background. Pups were induced at P14
381 or P15 with a single dose of tamoxifen (resuspended to 20mg/ml in Corn Oil with
382 10% ethanol) by intraperitoneal injection, at a concentration of 0.15mg per gram of
383 body weight. Pituitaries were harvested at the indicated time points post induction and
384 processed for further analysis as described below. Mice were harvested from different
385 litters for each time point at random. For litters in which there was a surplus of
386 experimental mice, multiple samples were harvested for each required time point.

387 For Wntless deletion studies, *Sox2^{CreERT2/+}; Wls^{fl/+}; ROSA26^{mTmG/mTmG}* males were bred
388 with *Wls^{fl/fl}; ROSA26^{mTmG/mTmG}* dams, to produce
389 *Sox2^{CreERT2/+}; Wls^{fl/+}; ROSA26^{mTmG/mTmG}*, *Sox2^{CreERT2/+}; Wls^{fl/fl}; ROSA26^{mTmG/mTmG}* and
390 *Wls^{fl/fl}; ROSA26^{mTmG/mTmG}* offspring. Pups of the indicated genotypes received
391 intraperitoneal injections of 0.15mg of tamoxifen/gram body weight on 4 consecutive
392 days, beginning at P14, and harvested 3 days after the final injection.

393 For the β -catenin loss-of-function experiments, either *Sox2*^{CreERT2/+}; *Ctnnb1*^{fl(ex2-}
394 ^{6)/+}; *ROSA26*^{mTmG/mTmG} or *Axin2*^{CreERT2/+}; *Ctnnb1*^{fl(ex2-6)/+}; *ROSA26*^{mTmG/mTmG} males were
395 crossed with *Ctnnb1*^{fl(ex2-6)/fl(ex2-6)/}; *ROSA26*^{mTmG/mTmG} dams. *Axin2*^{CreERT2/+}; *Ctnnb1*^{fl(ex2-}
396 ^{6)/fl(ex2-6)}; *ROSA26*^{mTmG/mTmG} and *Axin2*^{CreERT2/+}; *Ctnnb1*^{fl(ex2-6)/+}; *ROSA26*^{mTmG/mTmG} pups
397 were induced with a single dose of tamoxifen, at a concentration of 0.15mg per gram
398 of body weight and kept alive for 7 days before harvesting. *Sox2*^{CreERT2/+}; *Ctnnb1*^{fl(ex2-}
399 ^{6)/+}; *ROSA26*^{mTmG/mTmG} and *Sox2*^{CreERT2/+}; *Ctnnb1*^{fl(ex2-6)/fl(ex2-6)}; *ROSA26*^{mTmG/mTmG} pups
400 received two intraperitoneal injections of tamoxifen, at a concentration of
401 0.15mg/gram body weight, on two consecutive days and were kept alive for the
402 indicated length of time before harvesting.
403 *TCF/LEF:H2B-EGFP/+* mice culled and the pituitaries harvested at the indicated
404 ages for the respective experiments. For fluorescence-activated cell sorting
405 experiments, mice were harvested at 21 days of age.
406 *Axin2*^{CreERT2/+}; *Sox2*^{eGFP/+} *ROSA26*^{tdTomato/tdTomato} males were crossed with
407 *ROSA26*^{tdTomato/tdTomato} dams to produce *Axin2*^{CreERT2/+}; *Sox2*^{eGFP/+} *ROSA26*^{tdTomato/tdTomato}
408 that were induced with a single dose of tamoxifen at 21 days of age and harvested
409 three days later for fluorescence-activated cell sorting experiments.
410 For studies involving the induction of hypothyroidism, FVB/NJ mice were housed in
411 a conventional facility on a 12 hour light/12 hour dark cycle and were given chow and
412 water *ad libitum*. At weaning, P21 pups were either fed an iodine-deficient diet
413 supplemented with 0.15% propylthiouracil (PTU) or a normal maintenance diet for
414 control animals. Following 7 days of treatment, pituitaries were collected and fixed in
415 10% NBF for 18 hours at room temperature.
416
417 **Flow cytometry analysis of lineage traced pituitaries**

418 For the quantification of cells by flow cytometry, anterior lobes of
419 *Axin2^{CreERT2/+};ROSA26^{mTmG/+}* mice dissected at the indicated time points. The
420 posterior and intermediate lobes were dissected from the anterior lobes under a
421 dissection microscope. Untreated *ROSA26^{mTmG/+}* and wild type pituitaries from age-
422 matched litters were used as tdTomato only and negative controls, respectively.
423 Dissected pituitaries were incubated in Enzyme Mix (0.5% w/v collagenase type 2
424 (Lorne Laboratories), 0.1x Trypsin (Gibco), 50µg/ml DNase I (Worthington) and
425 2.5µg/ml Fungizone (Gibco) in Hank's Balanced Salt Solution (HBSS)(Gibco)) in a
426 cell culture incubator for up to 3 hours. 850ml of HBSS were added to each
427 Eppendorf in order to quench the reaction. Pituitaries were dissociated by agitation,
428 pipetting up and down 100x at first with a 1ml pipette, followed by 100x with a 200µl
429 pipette. Cells were transferred to a 15ml Falcon tube and resuspended in 9ml of HBSS
430 and spun down at 200g for 5 minutes. The supernatant was aspirated, leaving behind
431 the cell pellet that was resuspended in PBS and spun down at 1000rpm for 5 minutes
432 before being resuspended in a Live/Dead dye (Life Technologies, L34975) prepared
433 to manufacturer's instructions, for 30 minutes in the dark. Cells were washed in PBS
434 as above. The pellet was resuspended in FIX & PERM Cell Permeabilization Kit
435 (Life Technologies, GAS003) prepared as per manufacturer's instructions for 10
436 minutes at room temperature. Cells were washed as above, and the pellet was
437 resuspended in 500µl of FACS buffer (1% fetal calf serum (Sigma), 25mM HEPES in
438 PBS) and filtered through 70µm filters (BD Falcon), into 5ml round bottom
439 polypropylene tubes (BD Falcon). 1 minute prior to analysis, 1µl of Hoechst was
440 added to the suspended cells and incubated. Samples were analysed on a BD Fortessa,
441 and gated according to negative and single fluorophore controls. Single cells were
442 gated according to SSC-A and SSC-W. Dead cells were excluded according to DAPI

443 (2ng/ml, incubated for 2 mins prior to sorting). GFP⁺, tdTomato⁺ and
444 GFP⁺;tdTomato⁺ cells were gated according to negative controls in the PE-A and
445 FITC-A channels.

446

447 **Fluorescence Activated Cell Sorting for sequencing or colony forming assays**

448 For fluorescence activated cell sorting, the anterior lobes from *Sox2^{eGFP/+}*,
449 TCF/LEF:H2B-GFP or *Axin2^{CreERT2/+};ROSA26^{tdTomato};Sox2^{eGFP/+}* and their respective
450 controls were dissected and dissociated as above. After dissociation cells were spun
451 down at 200g in HBSS and the pellet was resuspended in 500µl FACS buffer. Using
452 an Aria III FACS machine (BD systems), samples were gated according to negative
453 controls, and where applicable single fluorophore controls. Experimental samples
454 were sorted according to their fluorescence, as indicated, into tubes containing either
455 RNAlater (Qiagen) for RNA isolation or 1ml of Pit Complete Media for culture ((Pit
456 Complete: 20ng/ml bFGF and 50ng/ml of cholera toxin in ‘Pit Basic’ media (DMEM-
457 F12 with 5% Fetal Calf Serum,100U/ml Penicillin and 100µg/ml Streptomycin). Cells
458 were plated in 12-well plates at clonal density, approximately 500 cells/well. Colonies
459 were incubated for 7 days total before being fixed in 10% neutral buffered formalin
460 (NBF) (Sigma) for 10 minutes at room temperature, washed for five minutes, three
461 times, mins with PBS and stained with crystal violet in order for the number of
462 colonies to be quantified.

463

464 **RNA-sequencing**

465 Total RNA was isolated from each sample and following poly-A selection, cDNA
466 libraries were generated using TruSeq (Clontech, 634925). Barcoded libraries were
467 then pooled at equal molar concentrations and sequenced on an Illumina Hiseq 4000

468 instrument in a 75 base pair, paired – end sequencing mode, at the Wellcome Trust
469 Centre for Human Genetics (Oxford, United Kingdom). Raw sequencing reads were
470 quality checked for nucleotide calling accuracy and trimmed accordingly to remove
471 potential sequencing primer contaminants. Following QC, forward and reverse reads
472 were mapped to GRCm38/mm10 using Hisat2 (Kim et al., 2015). Using a mouse
473 transcriptome specific GTF as a guide, FeatureCounts (Liao et al., 2014) was used to
474 generate gene count tables for every sample. These were utilised within the
475 framework of the Deseq2 (Love et al., 2014) and FPKM values (generated by FPKM
476 count (Wang et al., 2012)) were processed using the Cufflinks (Trapnell et al., 2012)
477 pipelines which identified statistically significant gene expression differences
478 between the sample groups. Following identification of differentially expressed genes
479 (at an FDR < 0.05) we focused on identifying differentially expressed pathways using
480 a significance threshold of FDR < 0.05 unless otherwise specified. The gene lists used
481 for Gene Set Enrichment Analysis (GSEA) were as found on the BROAD institute
482 GSEA MSigDBv.7 ‘molecular signatures database’. The deposited dataset can be
483 accessed through the following link:
484 <https://dataview.ncbi.nlm.nih.gov/object/PRJNA421806?reviewer=kr90aklsdtikh3gkh>
485 [3tdlpy30s](#)

486

487 **Immunofluorescence and microscopy**

488 Freshly harvested pituitaries were washed in PBS for 10 minutes before being fixed in
489 10% NBF for 18 hours at room temperature. In short, embryos and whole pituitaries
490 were washed in PBS 3 times, before being dehydrated through a series of 1 hour
491 washes in 25%, 50%, 70%, 80%, 90%, 95% and 100% ethanol. Tissues were washed
492 in Neo-Clear (Sigma) at room temperature for 10 minutes, then in fresh preheated

493 Neo-Clear at 60 °C for 10 minutes. Subsequently, a mixture of 50% Neo-Clear:50%
494 paraffin wax at 60°C for 15 minutes followed by three changes of pure wax for a
495 minimum of 1 hour washes at 60°C, before being orientated to be sectioned in the
496 frontal plane. Embedded samples were sectioned at 5µm and mounted on to Super
497 Frost+ slides.

498 For immunofluorescence, slides were deparaffinised in Neo-Clear for three times ten
499 minutes, washed in 100% ethanol for three times five minutes, and rehydrated in a
500 series of five minute ethanol washes up to distilled water (95%, 90%, 80%, 70%,
501 50%, 25%, H₂O). Heat induced epitope retrieval was performed with 1x DeClear
502 Buffer (citrate pH 6) in a Decloaking chamber NXGEN (Menarini Diagnostics) for 3
503 minutes at 110°C. Slides were left to cool to room temperature before proceeding to
504 block for 1 hour at room temperature in Blocking Buffer (0.2% BSA, 0.15% glycine,
505 0.1% TritonX in PBS) with 10% serum (sheep or donkey, depending on secondary
506 antibodies). Primary antibodies were diluted in blocking buffer with 1% of the
507 appropriate serum and incubated overnight at 4°C. Slides were washed three times for
508 10 minutes with PBST. Slides were incubated with secondary antibodies diluted
509 1:400 in blocking buffer with 1% serum for one hour at room temperature. Slides
510 were washed three times with PBST as above. Where biotinylated secondary
511 antibodies were used, slides were incubated with streptavidin diluted 1:400 in
512 blocking buffer with 1% serum for one hour at room temperature. Finally, slides were
513 washed with PBST and mounted using Vectashield Antifade Mounting Medium
514 (Vector Laboratories, H-1000).

515 The following antibodies, along with their dilutions and detection technique, were
516 used: GFP (1:400, Alexa Fluor-488 or -647 secondary), SOX2 raised in goat (1:200,
517 Alexa Fluor-488 secondary), SOX2 raised in rabbit (1:100, biotinylated secondary),

518 SOX9 (1:500, biotinylated secondary), PIT1 (1:500, biotinylated secondary), SF1
519 (1:300, biotinylated secondary), TPIT (1:200, biotinylated secondary), Ki-67 (1:100,
520 biotinylated secondary), pH-H3 (1:500, biotinylated secondary), GH (1:1000,
521 biotinylated secondary), TSH (1:1000, biotinylated secondary), PRL (1:1000,
522 biotinylated secondary), ACTH (1:400, Alexa Fluor-555 secondary), LH/FSH (1:300,
523 biotinylated secondary), ZO-1 (1:300, Alexa Fluor-488), E-Cadherin (1:300, Alexa
524 Fluor-488). Nuclei were visualized with Hoechst (1:1000). Images were taken on a
525 TCS SPS Confocal (Leica Microsystem) with a 20x objective for analysis.

526

527 **mRNA *In Situ* Hybridisation**

528 All mRNA *in situ* hybridisations were performed using the RNAscope singleplex or
529 duplex chromogenic kits (Advanced Cell Diagnostics) on formalin fixed paraffin
530 embedded sections processed as described in the above section. The protocol
531 followed the manufacturer's instructions with slight modifications. ImmEdge
532 Hydrophobic Barrier PAP Pen (Vector Laboratories, H-4000) was used to draw a
533 barrier around section while air-drying following the first ethanol washes.
534 Pretreatment followed the standard length of time for pituitaries (twelve minutes),
535 while embryos were boiled for 10 minutes. For singleplex, the protocol proceeded to
536 follow the instructions exactly. For duplex, Amplification 9 was extended to one hour
537 and the dilution of the Green Detection reagent was increased to 1:30. For both
538 protocols, sections were counterstained with Mayer's Haematoxylin (Vector
539 Laboratories, H-3404), left to dry at 60°C for 30 minutes before mounting with
540 VectaMount Permanent Mounting Medium (Vector Laboratories, H-5000). Slides
541 were scanned using a Nanozoomer-XR Digital Slide Scanner (Hamamatsu) and
542 processed using Nanozoomer Digital Pathology View (Hamamatsu).

543 **Quantification of cells**

544 Cell numbers were quantified in ImageJ using the cell counter plugin (Schindelin et
545 al., 2012). At a minimum, three sections per pituitary were quantified, spaced no less
546 than 100 μ M apart in the tissue.

547

548 **Statistics**

549 All statistical analyses were performed in GraphPad Prism. Data points in graphs
550 represent the mean values of recordings from a single biological replicate unless
551 otherwise stated.

552

553

554 **ACKNOWLEDGEMENTS**

555 This study has been supported by the Medical Research Council (MR/L016729/1,
556 MR/T012153/1) (C.L.A.), The Lister Institute of Preventive Medicine (C.L.A.), the
557 Deutsche Forschungsgemeinschaft (DFG German Research Foundation) (Project
558 Number 314061271 – TRR 205) (C.L.A.), the Howard Hughes Medical Institute
559 (R.N.), the Agence Nationale de la Recherche (ANR-18-CE14-0017) and Fondation
560 pour la Recherche Médicale (DEQ20150331732) (P.M.). J.P.R. was supported by a
561 Dianna Trebble Endowment Fund Dental Institute Studentship, E.J.L. by the King's
562 Bioscience Institute and the Guy's and St Thomas' Charity Prize PhD Programme in
563 Biomedical and Translational Science, Y.K. by a Project Support Grant from the
564 British Society for Neuroendocrinology. We thank Dr A.F. Parlow and the National
565 Hormone and Peptide Program (Harbor–University of California, Los Angeles
566 Medical Center) for providing some of the antibodies used in this study and Prof. J.
567 Drouin and Prof. S. Rhodes for TPIT and PIT1 antibodies respectively. We thank the

568 High-Throughput Genomics Group at the Wellcome Trust Centre for Human
569 Genetics (funded by Wellcome Trust grant reference 090532/Z/09/Z) for the
570 generation of the Sequencing data. For flow sorting and analysis, this research was
571 supported by the National Institute for Health Research (NIHR) Biomedical Research
572 Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College
573 London. We thank Marie Isabelle Garcia, Juan Pedro Martinez-Barbera and Paul Le
574 Tissier for useful discussions and critical comments on the manuscript.

575

576 **AUTHOR CONTRIBUTIONS**

577 Conceptualization C.L.A. and J.P.R.; Methodology J.P.R., C.L.A., P.M.; Investigation
578 J.P.R., V.Y., A.S., E.J.L., Sh.Ha., Sc.Ha., C.L.A., Y.K.; Resources R.N., B.W., M.F.,
579 X.L., Y.K., P.M.; Writing – Original Draft, C.L.A. and J.P.R.; Writing- Review &
580 Editing C.L.A., J.P.R. R.N., X.L., P.M.; Supervision C.L.A., R.N.; Funding
581 Acquisition C.L.A., R.N., P.M.

582

583

584

585 **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIF
Antibodies		
Anti-GFP, Chicken Polyclonal	Abcam	ab13970
Anti-SOX2, Goat Polyclonal	Immune Systems Ltd	GT15098
Anti-SOX2, Rabbit Monoclonal	Abcam	ab92494
Anti-SOX9, Rabbit Monoclonal	Abcam	ab185230
Anti PIT1, Rabbit Monoclonal	Gifted by S. Rhodes	N/A

Anti-SF1, Mouse Monoclonal	Life Technologies	N1665
Anti-TPIT, Rabbit Polyclonal	Gifted by J. Drouin	N/A
Anti-Ki67, Rabbit Monoclonal	Abcam	ab15580
Anti-pH-H3, Rabbit Polyclonal	Abcam	ab5176
Anti-GH, Rabbit Polyclonal	National Hormone and Peptide Program	AFP-5641801
Anti-TSH, Rabbit Polyclonal	National Hormone and Peptide Program	AFP-1274789
Anti-PRL, Rabbit Polyclonal	National Hormone and Peptide Program	AFP-4251091
Anti-ACTH, Mouse Monoclonal	Fitzgerald	10C-CR1096M1
Anti-LH, Rabbit Polyclonal	National Hormone and Peptide Program	AFP-697071P
Anti-FSH, Rabbit Polyclonal	National Hormone and Peptide Program	AFP-HFS6
Anti-ZO-1, Rat Monoclonal	Santa Cruz	SC33725
Anti-E-CADHERIN, Rabbit Monoclonal	Cell Signaling	3195S
Anti-rabbit 488, Goat Polyclonal	Life Technologies	A11008
Anti-rabbit 555, Goat Polyclonal	Life Technologies	A21426
Anti-rabbit 633, Goat Polyclonal	Life Technologies	A21050
Anti-goat 488, Donkey Polyclonal	Abcam	ab150133
Anti-chicken 488, Goat Polyclonal	Life Technologies	A11039

Anti-chicken 647, Goat Polyclonal	Life Technologies	A21449
Anti-Rat 555, Goat Polyclonal	Life Technologies	A21434
Anti-Mouse 555, Goat Polyclonal	Life Technologies	A21426
Anti-rabbit biotinylated, Donkey Polyclonal	Abcam	ab620
Anti-rabbit biotinylated, Goat Polyclonal	Abcam	ab207999
Anti-mouse biotinylated, Goat Biotinylated	Abcam	ab6788
Streptavidin 488	Life Technologies	S11223
Streptavidin 555	Life Technologies	S32355
Streptavidin 633	Life Technologies	S21375
Chemicals, Peptides, and Recombinant Proteins		
Tamoxifen	Sigma	T5648
Corn Oil	Sigma	C8267
Collagenase Type 2	Worthington	4178
10X Trypsin	Sigma	59418C
DNase	Worthington	LS002172
Fungizone	Gibco	15290
Hank's Balanced Salt Solution (HBSS)	Gibco	14170
Fetal Calf Serum	Sigma	
HEPES	Thermo Fisher	15630
bFGF	R&D Systems	233-FB-025
Cholera Toxin	Sigma	C8052
DMEM-F12	Thermo Fisher	31330
Penicillin/Streptomycin	Gibco	15070-063

Neutral Buffered Formalin	Sigma	HT501128
Hoechst 33342	Thermo Fisher	H3570
Declere	Sigma	D3565
Neo-Clear	Sigma	65351-M
4X Lysis Buffer	Bio Rad	161-0747
Iodine-deficient diet with propylthiouracil PTU	Envigo	TD.95125
Control maintenance diet	SAFE	U8231G1 OR
Critical Commercial Assays		
RNAScope 2.5 HD Assay -RED	Advanced Cell Diagnostics	322350
RNAScope 2.5 HD Duplex Assay	Advanced Cell Diagnostics	322430
Live/Dead dye	Life Technologies	L34975
Fix and Perm	Life Technologies	GAS003
Deposited Data		
RNA-Seq	BioProject (NCBI)	PRJNA42 1806
Experimental Models: Cell Lines		
Mouse: Primary pituitary cells	This Study	N/A
Experimental Models: Organisms/Strains		

Mouse: <i>Axin2</i> ^{CreERT2/+}	The Jackson Laboratory Roel Nusse, Stanford University	018867
Mouse: <i>Sox2</i> ^{CreERT2/+}	Andoniadou, 2013	N/A
Mouse: <i>ROSA26</i> ^{mTmG/mTmG}	The Jackson Laboratory	007676
Mouse: <i>ROSA26</i> ^{Confetti/Confetti}	The Jackson Laboratory	017492
Mouse: <i>Ctnnb1</i> ^{fl(ex2-6)/fl(ex2-6)}	The Jackson Laboratory	004152
Mouse: <i>Wls</i> ^{fl/fl}	The Jackson Laboratory	012888
Mouse: <i>Sfl</i> ^{Cre/+} ; <i>ROSA26</i> ^{Rspol/+}	Andreas Schedl, University of Nice	N/A
Mouse <i>Sox2</i> ^{eGFP/+}	Ellis et al, 2004	N/A
Mouse: <i>TCF/Lef:H2B-GFP</i>	The Jackson Laboratory	013752
Mouse FVB/NJ	The Jackson Laboratory	001800
Oligonucleotides		
RNAscope probe: <i>Axin2</i>	Advanced Cell Diagnostics	400331
RNAscope probe: <i>Lef1</i>	Advanced Cell Diagnostics	441861
RNAscope probe: <i>Wls</i>	Advanced Cell Diagnostics	405011
RNAscope probe: <i>Rspol</i>	Advanced Cell Diagnostics	401991

RNAscope probe: <i>Rspo2</i>	Advanced Cell Diagnostics	402001
RNAscope probe: <i>Rspo3</i>	Advanced Cell Diagnostics	402011
RNAscope probe: <i>Rspo4</i>	Advanced Cell Diagnostics	402021
RNAscope probe: <i>Lgr4</i>	Advanced Cell Diagnostics	318321
RNAscope probe: <i>Wnt9a</i>	Advanced Cell Diagnostics	405081
RNAscope probe: <i>Wnt2</i>	Advanced Cell Diagnostics	313601
RNAscope probe: <i>Wnt5a</i>	Advanced Cell Diagnostics	316791
RNAscope probe: <i>eGFP</i>	Advanced Cell Diagnostics	400281
RNAscope probe: <i>Jun</i>	Advanced Cell Diagnostics	453561
RNAscope probe: <i>Axin2</i> (Channel 2)	Advanced Cell Diagnostics	400331- C2
RNAscope probe: <i>Sox2</i> (Channel 2)	Advanced Cell Diagnostics	401041- C2
RNAscope probe: <i>eGFP</i> (Channel 2)	Advanced Cell Diagnostics	400281- C2

RNAscope probe: <i>Sox2</i>	Advanced Cell Diagnostics	401041
RNAscope probe: <i>Pou1f1</i>	Advanced Cell Diagnostics	486441
RNAscope probe: Duplex Positive Control <i>Ppib-C1, Polr2a-C2</i>	Advanced Cell Diagnostics	321641
RNAscope probe: Duplex Negative Control <i>DapB both channels</i>	Advanced Cell Diagnostics	320751
RNAscope probe: Singleplex Positive Control <i>Ppib</i>	Advanced Cell Diagnostics	313911
RNAscope probe: Singleplex Negative Control <i>DapB</i>	Advanced Cell Diagnostics	310043
Software and Algorithms		
FlowJo	FlowJo, LLC	https://www.flowjo.com/
Prism 7	GraphPad Software	https://www.graphpad.com/
Image Lab	Bio-Rad Laboratories	http://www.bio-rad.com/

NDP View	Hamamatsu Photonics	https://www.hamamatsu.com/
HISAT v2.0.3	(Kim, Langmead, & Salzberg, 2015)	https://github.com/philobio/hisat2
DESeq2 v2.11.38	(Love, Huber, & Anders, 2014)	https://github.com/Bioconductor/mirror/DESeq2
FeatureCounts v1.4.6p5	(Liao, Smyth, & Shi, 2014)	http://subread.sourceforge.net/
The Galaxy Platform	(Afgan et al., 2016; Blankenberg et al., 2010; Goecks, Nekrutenko, & Taylor, 2010)	https://usegalaxy.org
Gene Set Enrichment Analysis (GSEA)	Subramanian et al, PNAS, 2005	software.broadinstitute.org/gsea/index.jsp

Cufflinks	(Trapnell et al., 2012)	https://github.com/cole-trapnell-lab/cufflinks
Other		

586

587

588 **REFERENCES**

- 589 Alatzoglou, K.S., Andoniadou, C.L., Kelberman, D., Buchanan, C.R., Crolla, J.,
590 Arriazu, M.C., Roubicek, M., Moncet, D., Martinez-Barbera, J.P., and Dattani, M.T.
591 (2011). SOX2 haploinsufficiency is associated with slow progressing hypothalamo-
592 pituitary tumours. *Human mutation* 32, 1376-1380.
- 593 Andoniadou, C.L., Gaston-Massuet, C., Reddy, R., Schneider, R.P., Blasco, M.A., Le
594 Tissier, P., Jacques, T.S., Pevny, L.H., Dattani, M.T., and Martinez-Barbera, J.P.
595 (2012). Identification of novel pathways involved in the pathogenesis of human
596 adamantinomatous craniopharyngioma. *Acta neuropathologica* 124, 259-271.
- 597 Andoniadou, Cynthia L., Matsushima, D., Mousavy Gharavy, Seyedeh N., Signore,
598 M., Mackintosh, Albert I., Schaeffer, M., Gaston-Massuet, C., Mollard, P., Jacques,
599 Thomas S., Le Tissier, P., *et al.* (2013). Sox2+ Stem/Progenitor Cells in the Adult
600 Mouse Pituitary Support Organ Homeostasis and Have Tumor-Inducing Potential.
601 *Cell stem cell* 13, 433-445.
- 602 Arnold, K., Sarkar, A., Yram, M.A., Polo, J.M., Bronson, R., Sengupta, S., Seandel,
603 M., Geijsen, N., and Hochedlinger, K. (2011). Sox2(+) adult stem and progenitor cells
604 are important for tissue regeneration and survival of mice. *Cell stem cell* 9, 317-329.
- 605 Azzolin, L., Panciera, T., Soligo, S., Enzo, E., Bicciato, S., Dupont, S., Bresolin, S.,
606 Frasson, C., Basso, G., Guzzardo, V., *et al.* (2014). YAP/TAZ Incorporation in the
607 beta-Catenin Destruction Complex Orchestrates the Wnt Response. *Cell* 158, 157-
608 170.

609 Basham, K.J., Rodriguez, S., Turcu, A.F., Lerario, A.M., Logan, C.Y., Rysztak, M.R.,
610 Gomez-Sanchez, C.E., Breault, D.T., Koo, B.K., Clevers, H., *et al.* (2019). A ZNRF3-
611 dependent Wnt/beta-catenin signaling gradient is required for adrenal homeostasis.
612 *Genes & development* 33, 209-220.

613 Bilodeau, S., Roussel-Gervais, A., and Drouin, J. (2009). Distinct developmental roles
614 of cell cycle inhibitors p57Kip2 and p27Kip1 distinguish pituitary progenitor cell
615 cycle exit from cell cycle reentry of differentiated cells. *Molecular and cellular*
616 *biology* 29, 1895-1908.

617 Carbajo-Perez, E., and Watanabe, Y.G. (1990). Cellular proliferation in the anterior
618 pituitary of the rat during the postnatal period. *Cell Tissue Res* 261, 333-338.

619 Carpenter, A.C., Rao, S., Wells, J.M., Campbell, K., and Lang, R.A. (2010).
620 Generation of mice with a conditional null allele for Wntless. *Genesis* 48, 554-558.

621 Castinetti, F., Davis, S.W., Brue, T., and Camper, S.A. (2011). Pituitary stem cell
622 update and potential implications for treating hypopituitarism. *Endocr Rev* 32, 453-
623 471.

624 Clevers, H., and Watt, F.M. (2018). Defining Adult Stem Cells by Function, not by
625 Phenotype. *Annu Rev Biochem* 87, 1015-1027.

626 Cox, B., Laporte, E., Vennekens, A., Kobayashi, H., Nys, C., Van Zundert, I., Uji,
627 I.H., Vercauteren Drubbel, A., Beck, B., Roose, H., *et al.* (2019). Organoids from
628 pituitary as a novel research model toward pituitary stem cell exploration. *The Journal*
629 *of endocrinology* 240, 287-308.

630 Davis, S.W., Mortensen, A.H., and Camper, S.A. (2011). Birthdating studies reshape
631 models for pituitary gland cell specification. *Developmental biology* 352, 215-227.

632 Deschene, E.R., Myung, P., Rompolas, P., Zito, G., Sun, T.Y., Taketo, M.M.,
633 Saotome, I., and Greco, V. (2014). beta-Catenin activation regulates tissue growth
634 non-cell autonomously in the hair stem cell niche. *Science (New York, NY)* 343,
635 1353-1356.

636 Doupe, D.P., Marshall, O.J., Dayton, H., Brand, A.H., and Perrimon, N. (2018).
637 *Drosophila* intestinal stem and progenitor cells are major sources and regulators of
638 homeostatic niche signals. *Proceedings of the National Academy of Sciences of the*
639 *United States of America* 115, 12218-12223.

640 Fauquier, T., Rizzoti, K., Dattani, M., Lovell-Badge, R., and Robinson, I.C. (2008).
641 SOX2-expressing progenitor cells generate all of the major cell types in the adult
642 mouse pituitary gland. *Proc Natl Acad Sci U S A* 105, 2907-2912.

643 Ferrer-Vaquero, A., Piliszek, A., Tian, G., Aho, R.J., Dufort, D., and Hadjantonakis,
644 A.K. (2010). A sensitive and bright single-cell resolution live imaging reporter of
645 Wnt/ss-catenin signaling in the mouse. *BMC Dev Biol* *10*, 121.

646 Gaston-Massuet, C., Andoniadou, C.L., Signore, M., Jayakody, S.A., Charolidi, N.,
647 Kyeyune, R., Vernay, B., Jacques, T.S., Taketo, M.M., Le Tissier, P., *et al.* (2011).
648 Increased Wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to
649 pituitary tumors in mice and humans. *Proceedings of the National Academy of*
650 *Sciences of the United States of America* *108*, 11482-11487.

651 Gonzalez-Meljem, J.M., Haston, S., Carreno, G., Apps, J.R., Pozzi, S., Stache, C.,
652 Kaushal, G., Virasami, A., Panousopoulos, L., Mousavy-Gharavy, S.N., *et al.* (2017).
653 Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse
654 models of paediatric craniopharyngioma. *Nature communications* *8*, 1819.

655 Gregorieff, A., Liu, Y., Inanlou, M.R., Khomchuk, Y., and Wrana, J.L. (2015). Yap-
656 dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and
657 cancer. *Nature advance online publication*.

658 Gremeaux, L., Fu, Q., Chen, J., and Vankelecom, H. (2012). Activated phenotype of
659 the pituitary stem/progenitor cell compartment during the early-postnatal maturation
660 phase of the gland. *Stem Cells Dev* *21*, 801-813.

661 Haston, S., Pozzi, S., Carreno, G., Manshaei, S., Panousopoulos, L., Gonzalez-
662 Meljem, J.M., Apps, J.R., Virasami, A., Thavaraj, S., Gutteridge, A., *et al.* (2017).
663 MAPK pathway control of stem cell proliferation and differentiation in the embryonic
664 pituitary provides insights into the pathogenesis of papillary craniopharyngioma.
665 *Development (Cambridge, England)* *144*, 2141-2152.

666 Higuchi, M., Yoshida, S., Kanno, N., Mitsuishi, H., Ueharu, H., Chen, M., Nishimura,
667 N., Kato, T., and Kato, Y. (2017). Clump formation in mouse pituitary-derived non-
668 endocrine cell line Tpit/F1 promotes differentiation into growth-hormone-producing
669 cells. *Cell Tissue Res* *369*, 353-368.

670 Iwai-Liao, Y., Kumabe, S., Takeuchi, M., and Higashi, Y. (2000).
671 Immunohistochemical localisation of epidermal growth factor, transforming growth
672 factor alpha and EGF receptor during organogenesis of the murine hypophysis in
673 vivo. *Okajimas Folia Anat Jpn* *76*, 291-301.

674 Kelberman, D., de Castro, S.C., Huang, S., Crolla, J.A., Palmer, R., Gregory, J.W.,
675 Taylor, D., Cavallo, L., Faienza, M.F., Fischetto, R., *et al.* (2008). SOX2 plays a

676 critical role in the pituitary, forebrain, and eye during human embryonic development.
677 *J Clin Endocrinol Metab* *93*, 1865-1873.

678 Kim, D., Langmead, B., and Salzberg, S.L. (2015). HISAT: a fast spliced aligner with
679 low memory requirements. *Nat Methods* *12*, 357-360.

680 Levy, A. (2002). Physiological implications of pituitary trophic activity. *The Journal*
681 *of endocrinology* *174*, 147-155.

682 Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general
683 purpose program for assigning sequence reads to genomic features. *Bioinformatics*
684 *30*, 923-930.

685 Lim, X., Tan, S.H., Koh, W.L., Chau, R.M., Yan, K.S., Kuo, C.J., van Amerongen,
686 R., Klein, A.M., and Nusse, R. (2013). Interfollicular epidermal stem cells self-renew
687 via autocrine Wnt signaling. *Science (New York, NY)* *342*, 1226-1230.

688 Lodge, E.J., Russell, J.P., Patist, A.L., Francis-West, P., and Andoniadou, C.L.
689 (2016). Expression Analysis of the Hippo Cascade Indicates a Role in Pituitary Stem
690 Cell Development. *Frontiers in physiology* *7*, 114.

691 Lodge, E.J., Santambrogio, A., Russell, J.P., Xekouki, P., Jacques, T.S., Johnson,
692 R.L., Thavaraj, S., Bornstein, S.R., and Andoniadou, C.L. (2019). Homeostatic and
693 tumorigenic activity of SOX2+ pituitary stem cells is controlled by the
694 LATS/YAP/TAZ cascade. *eLife* *8*.

695 Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change
696 and dispersion for RNA-seq data with DESeq2. *Genome Biol* *15*, 550.

697 Moiseenko, A., Kheirollahi, V., Chao, C.M., Ahmadvand, N., Quantius, J., Wilhelm,
698 J., Herold, S., Ahlbrecht, K., Morty, R.E., Rizvanov, A.A., *et al.* (2017). Origin and
699 characterization of alpha smooth muscle actin-positive cells during murine lung
700 development. *Stem cells (Dayton, Ohio)* *35*, 1566-1578.

701 Nabhan, A.N., Brownfield, D.G., Harbury, P.B., Krasnow, M.A., and Desai, T.J.
702 (2018). Single-cell Wnt signaling niches maintain stemness of alveolar type 2 cells.
703 *Science (New York, NY)* *359*, 1118-1123.

704 Nolan, L.A., Kavanagh, E., Lightman, S.L., and Levy, A. (1998). Anterior pituitary
705 cell population control: basal cell turnover and the effects of adrenalectomy and
706 dexamethasone treatment. *J Neuroendocrinol* *10*, 207-215.

707 Ohlstein, B., and Spradling, A. (2007). Multipotent *Drosophila* intestinal stem cells
708 specify daughter cell fates by differential notch signaling. *Science (New York, NY)*
709 *315*, 988-992.

710 Osmundsen, A.M., Keisler, J.L., Taketo, M.M., and Davis, S.W. (2017). Canonical
711 WNT Signaling Regulates the Pituitary Organizer and Pituitary Gland Formation.
712 *Endocrinology* *158*, 3339-3353.

713 Palma, V., Lim, D.A., Dahmane, N., Sanchez, P., Brionne, T.C., Herzberg, C.D.,
714 Gitton, Y., Carleton, A., Alvarez-Buylla, A., and Ruiz i Altaba, A. (2005). Sonic
715 hedgehog controls stem cell behavior in the postnatal and adult brain. *Development*
716 (Cambridge, England) *132*, 335-344.

717 Pardo-Saganta, A., Tata, P.R., Law, B.M., Saez, B., Chow, R.D., Prabhu, M., Gridley,
718 T., and Rajagopal, J. (2015). Parent stem cells can serve as niches for their daughter
719 cells. *Nature* *523*, 597-601.

720 Perez Millan, M.I., Brinkmeier, M.L., Mortensen, A.H., and Camper, S.A. (2016).
721 PROP1 triggers epithelial-mesenchymal transition-like process in pituitary stem cells.
722 *eLife* *5*.

723 Pevny, L., and Rao, M.S. (2003). The stem-cell menagerie. *Trends Neurosci* *26*, 351-
724 359.

725 Potok, M.A., Cha, K.B., Hunt, A., Brinkmeier, M.L., Leitges, M., Kispert, A., and
726 Camper, S.A. (2008). WNT signaling affects gene expression in the ventral
727 diencephalon and pituitary gland growth. *Developmental dynamics : an official*
728 *publication of the American Association of Anatomists* *237*, 1006-1020.

729 Rizzoti, K., Akiyama, H., and Lovell-Badge, R. (2013). Mobilized adult pituitary
730 stem cells contribute to endocrine regeneration in response to physiological demand.
731 *Cell stem cell* *13*, 419-432.

732 Roose, H., Cox, B., Boretto, M., Gysemans, C., Vennekens, A., and Vankelecom, H.
733 (2017). Major depletion of SOX2(+) stem cells in the adult pituitary is not restored
734 which does not affect hormonal cell homeostasis and remodelling. *Sci Rep* *7*, 16940.

735 Sarkar, A., Huebner, A.J., Sulahian, R., Anselmo, A., Xu, X., Flattery, K., Desai, N.,
736 Sebastian, C., Yram, M.A., Arnold, K., *et al.* (2016). Sox2 Suppresses Gastric
737 Tumorigenesis in Mice. *Cell reports* *16*, 1929-1941.

738 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T.,
739 Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., *et al.* (2012). Fiji: an open-source
740 platform for biological-image analysis. *Nat Methods* *9*, 676-682.

741 Schofield, R. (1978). The relationship between the spleen colony-forming cell and the
742 haemopoietic stem cell. *Blood Cells* *4*, 7-25.

743 Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette,
744 M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., *et al.* (2005). Gene set
745 enrichment analysis: a knowledge-based approach for interpreting genome-wide
746 expression profiles. *Proceedings of the National Academy of Sciences of the United*
747 *States of America* *102*, 15545-15550.

748 Syed, S.M., Kumar, M., Ghosh, A., Tomasetig, F., Ali, A., Whan, R.M., Alterman,
749 D., and Tanwar, P.S. (2020). Endometrial Axin2(+) Cells Drive Epithelial
750 Homeostasis, Regeneration, and Cancer following Oncogenic Transformation. *Cell*
751 *stem cell* *26*, 64-80 e13.

752 Takase, H.M., and Nusse, R. (2016). Paracrine Wnt/beta-catenin signaling mediates
753 proliferation of undifferentiated spermatogonia in the adult mouse testis. *Proceedings*
754 *of the National Academy of Sciences of the United States of America* *113*, E1489-
755 1497.

756 Takeo, M., Chou, W.C., Sun, Q., Lee, W., Rabbani, P., Loomis, C., Taketo, M.M.,
757 and Ito, M. (2013). Wnt activation in nail epithelium couples nail growth to digit
758 regeneration. *Nature* *499*, 228-232.

759 Tan, D.W., and Barker, N. (2014). Intestinal stem cells and their defining niche.
760 *Current topics in developmental biology* *107*, 77-107.

761 Taniguchi, Y., Yasutaka, S., Kominami, R., and Shinohara, H. (2002). Mitoses of
762 thyrotrophs contribute to the proliferation of the rat pituitary gland during the early
763 postnatal period. *Anat Embryol (Berl)* *206*, 67-72.

764 Tata, P.R., and Rajagopal, J. (2016). Regulatory Circuits and Bi-directional Signaling
765 between Stem Cells and Their Progeny. *Cell stem cell* *19*, 686-689.

766 Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D.R., Pimentel, H.,
767 Salzberg, S.L., Rinn, J.L., and Pachter, L. (2012). Differential gene and transcript
768 expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc*
769 *7*, 562-578.

770 van Amerongen, R., Bowman, A.N., and Nusse, R. (2012). Developmental stage and
771 time dictate the fate of Wnt/beta-catenin-responsive stem cells in the mammary gland.
772 *Cell stem cell* *11*, 387-400.

773 Vidal, V., Sacco, S., Rocha, A.S., da Silva, F., Panzolini, C., Dumontet, T., Doan,
774 T.M., Shan, J., Rak-Raszewska, A., Bird, T., *et al.* (2016). The adrenal capsule is a
775 signaling center controlling cell renewal and zonation through Rspo3. *Genes &*
776 *development* *30*, 1389-1394.

777 Wang, B., Zhao, L., Fish, M., Logan, C.Y., and Nusse, R. (2015). Self-renewing
778 diploid Axin2(+) cells fuel homeostatic renewal of the liver. *Nature* 524, 180-185.

779 Wang, L., Wang, S., and Li, W. (2012). RSeQC: quality control of RNA-seq
780 experiments. *Bioinformatics* 28, 2184-2185.

781 Willems, C., Fu, Q., Roose, H., Mertens, F., Cox, B., Chen, J., and Vankelecom, H.
782 (2016). Regeneration in the Pituitary After Cell-Ablation Injury: Time-Related
783 Aspects and Molecular Analysis. *Endocrinology* 157, 705-721.

784 Xekouki, P., Lodge, E.J., Matschke, J., Santambrogio, A., Apps, J.R., Sharif, A.,
785 Jacques, T.S., Aylwin, S., Prevot, V., Li, R., *et al.* (2018). Non-secreting pituitary
786 tumours characterised by enhanced expression of YAP/TAZ. *Endocrine-related*
787 *cancer*.

788 Xekouki, P., Lodge, E.J., Matschke, J., Santambrogio, A., Apps, J.R., Sharif, A.,
789 Jacques, T.S., Aylwin, S., Prevot, V., Li, R., *et al.* (2019). Non-secreting pituitary
790 tumours characterised by enhanced expression of YAP/TAZ. *Endocrine-related*
791 *cancer* 26, 215-225.

792 Yan, K.S., Janda, C.Y., Chang, J., Zheng, G.X.Y., Larkin, K.A., Luca, V.C., Chia,
793 L.A., Mah, A.T., Han, A., Terry, J.M., *et al.* (2017). Non-equivalence of Wnt and R-
794 spondin ligands during Lgr5(+) intestinal stem-cell self-renewal. *Nature* 545, 238-
795 242.

796 Yoshida, S., Kato, T., Higuchi, M., Chen, M., Ueharu, H., Nishimura, N., and Kato,
797 Y. (2015). Localization of juxtacrine factor ephrin-B2 in pituitary stem/progenitor cell
798 niches throughout life. *Cell Tissue Res* 359, 755-766.

799 Yoshida, S., Kato, T., Kanno, N., Nishimura, N., Nishihara, H., Horiguchi, K., and
800 Kato, Y. (2017). Cell type-specific localization of Ephs pairing with ephrin-B2 in the
801 rat postnatal pituitary gland. *Cell Tissue Res* 370, 99-112.

802 Zhu, X., Tollkuhn, J., Taylor, H., and Rosenfeld, M.G. (2015). Notch-Dependent
803 Pituitary SOX2(+) Stem Cells Exhibit a Timed Functional Extinction in Regulation of
804 the Postnatal Gland. *Stem Cell Reports* 5, 1196-1209.

805

806

807

808

809 **FIGURES**


810 **Figure 1. *Axin2* expressing cells contribute to pituitary growth and expansion of**

811 **all lineages**

- 812 A. Immunofluorescence staining against GFP (green) with markers of PSCs or
813 lineage commitment (magenta) in *Axin2*^{CreERT2/+}; *Rosa26*^{mTmG/+} pituitaries
814 harvested from mice induced at P14 and lineage traced for 2 days (top panel) and
815 14 days (bottom panel). Scale bar 10µm.
- 816 B. Quantification of lineage expansion between 2 and 14 days following induction at
817 P14. Graph shows that the proportion of lineage committed cells (either PIT1⁺,
818 TPIT⁺ or SF1⁺) and PSCs (SOX2⁺), i.e. that are transcription factor (TF)⁺ cells
819 that are GFP⁺ increases between 2 days (black bars) and 14 days (grey bars) post
820 induction. PIT1 *P*=0.000004, TPIT *P*=0.008 multiple *t*-tests. n = 4 animals per
821 time point.
- 822 C. Immunofluorescence staining against GFP (green) in pituitaries harvested from
823 *Axin2*^{CreERT2/+}; *Rosa26*^{mTmG/+} mice induced at P14 and lineage traced for 2 days, 2
824 weeks and 8 weeks. Bottom panel shows magnified fields of view of regions of
825 interest indicated by white boxes in panels above. Scale bars 50µm.
- 826 D. Top panel showing the quantification of the proportion of all cells in
827 *Axin2*^{CreERT2/+}; *Rosa26*^{mTmG/+} pituitaries that are GFP⁺ at 2, 7, 14, 28 and 56 days
828 post induction as analysed by flow cytometry. Day 2 to 7 *P*<0.0001 unpaired *t*-
829 test. (Bottom) Graph of the absolute number of GFP⁺ cells (green) and as a
830 proportion of total cells (blue) at the time points indicated.
- 831 E. X-gal staining in *Axin2*^{CreERT2/+}; *Rosa26*^{LacZ/+} pituitaries harvested from mice
832 induced at P14 and lineage traced for 8 weeks (left) and 1 year (right).

833 F. Model summarising the major contribution of WNT-responsive progenitors of all
 834 lineages to pituitary growth, in addition to that of SOX2⁺ PSCs.
 835
 836

Figure 1



837 **Figure 2. Activation of WNT signalling in SOX2⁺ PSCs and their descendants is**
838 **necessary for long-term growth**

839 A. Schematic of the experimental timeline used in panels A and B. Endogenous

840 expression of tdTomato (magenta, *Axin2* targeted cells) and EGFP (green, *Sox2*

841 expressing cells) in *Axin2^{CreERT2/+};Sox2^{Egfp/+};Rosa26^{tdTomato/+}* pituitaries harvested

842 at P24 sectioned in the frontal plane. Nuclei are counterstained with Hoechst in

843 the merged panel. Scale bar 50µm

844 B. A representative culture plate showing colonies derived from Tomato⁺, EGFP⁺ or

845 Tomato⁺;EGFP⁺ cells that were isolated from

846 *Axin2^{CreERT2/+};Sox2^{Egfp/+};Rosa26^{tdTomato/+}* pituitaries by FACS plated in stem cell

847 promoting media at clonogenic densities and stained with crystal violet (left

848 panel). The proportion of colony-forming cells in each subpopulation were

849 quantified by counting the number of colonies per well (right panel). Each data

850 point indicates individual wells. $P=0.0226$, Mann-Whitney U test (two-tailed).

851 C. Immunofluorescence staining against SOX2 (green) and Ki-67 (magenta) in

852 *Sox2^{+/+}Ctnnb1^{LOF/LOF}* (control) and *Sox2^{CreERT2/+}Ctnnb1^{LOF/LOF}* (mutant) pituitaries

853 from mice induced at P14 and analysed 22 weeks after induction (at P168)

854 (bottom panel). Scale bar 50µm.

855 D. Dorsal view of whole mount pituitaries of *Sox2^{+/+};Ctnnb1^{LOF/LOF}* (control) and

856 *Sox2^{CreERT2/+};Ctnnb1^{LOF/LOF}* (mutant), 22 weeks after induction (i.e. P168).

857 E. Model summarising the effect of *Ctnnb1* deletion in SOX2⁺ PSCs.


858

859 PL, posterior lobe; IL, intermediate lobe; AL, anterior lobe. All plotted points equal

860 one technical replicate, n = 5 biological replicates.

861


Figure 2



862 **Figure 3. SOX2⁺ PSCs are as a source of WNT ligands in the pituitary**

- 863 A. Immunofluorescence staining against GFP (green) and SOX2 (magenta) in
864 *Axin2^{CreERT2/+}; Rosa26^{mTmG/+}* pituitaries 48 hours post induction. Graph
865 representing a quantification of the proximity of individual GFP⁺ cells to the
866 nearest SOX2⁺ cell as quantified by the number of nuclei separating them. Scale
867 bars 50µm.
- 868 B. Experimental paradigm for RNA Seq analysis of *Sox2* positive and negative cells.
- 869 C. Graphs representing the FPKM values of *Wls* and *Porcupine* in *Sox2* positive and
870 negative cells (black and grey bars, respectively). mRNA in situ hybridisation for
871 *Sox2* and for *Wls* on wild type sagittal pituitaries at P14, demonstrating strong *Wls*
872 expression in the marginal zone epithelium. Scale bars 250µm.
- 873 D. Bar chart showing the FPKM values of *Wnt* genes in the *Sox2*⁺ and *Sox2*⁻
874 fractions. Double mRNA in situ hybridisation against *Wnt2*, *Wnt5a* and *Wnt9a*
875 (blue) together with *Sox2* (red) validating expression in the *Sox2*⁺ population.
876 Boxed regions through the marginal zone epithelium are magnified. Scale bars
877 100µm and 50µm in boxed inserts.
- 878
- 879
- 880

Figure 3




881 **Figure 4. Paracrine secretion of WNTs from SOX2⁺ PSCs is necessary for**
882 **expansion of committed cells**

883 A. Immunofluorescence staining against SOX2 (green) and Ki-67 (magenta) in
884 *Sox2^{+/+}; Wls^{fl/fl}* (control) and *Sox2^{CreERT2/+}; Wls^{fl/fl}* (mutant) pituitaries induced from
885 P14 and analysed after one week. Nuclei were counterstained with Hoechst. (i)
886 and (ii) represent magnified fields of view of regions indicated by white boxes in
887 top panels. Scale bars 50µm. Graph of quantification of cycling cells marked by
888 Ki-67 among cells negative for SOX2. Values represent mean +/- SEM,
889 $P=0.0008$, unpaired *t*-test. Graph of quantification of cycling cells marked by Ki-
890 67 among SOX2-positive cells. Values represent mean +/- SEM, $P=0.0121$,
891 unpaired *t*-test.

892 B. Double mRNA in situ hybridisation using specific probes against *Lef1* (blue) and
893 *Sox2* (red) in control and mutant pituitaries following tamoxifen induction from
894 P14 and tracing for 7 days. Scale bars 250µm and 50µm in boxed regions.

895 C. Model summarising paracrine WNT secretion from SOX2⁺ PSCs to lineage-
896 committed progenitors and the effects of abolishing WNT secretion from SOX2⁺
897 PSCs through the deletion of *Wls*.
898

Figure 4



Sox2^{+/+}; Wls^{fl/fl}

Lef1/Sox2

Sox2^{CreERT2/+}; Wls^{fl/fl}

P14 + 7 days

Wild type

Wls deletion in SOX2⁺